Seattle-based Parse Biosciences is partnering with Decode Science to provide Parse’s single-cell RNA-sequencing solution in Australia and New Zealand, a news release said.
“The Parse team is elated to include Australia and New Zealand in the global expansion,” the company's CEO and co-founder Alex Rosengerg said in a statement. “We see these markets contributing substantially to our success and found the perfect partner in Decode.”
Single-cell sequencing is used by researchers developing treatments for cancers, kidney and liver disease, tissue repair and other diseases, the company said.
"Parse Biosciences is providing researchers with the ability to perform single-cell sequencing with unprecedented scale and ease," the company said. Parse's solution "transforms each cell into a unique reaction compartment instead of physically isolating the cells."
This helps lower data contamination rates, making sequencing more efficient and eliminates the need to limit cell size.
"Decode Science is excited to bring Parse Biosciences to the Australian and New Zealand life science community,” Josh Warburton, managing director of Decode Science said in a statement. “Parse Biosciences’ technology moves single-cell results beyond the limitations inherent in current techniques, enabling our customers to publish faster, in higher impact journals.”